Advertisement
Screener

Crown Electrokinetics Corp. Spending and interest coverage

Crown Electrokinetics Corp. Spending and interest coverage

  • R&D / revenue · 12 months: Value 16.92%; Formula and calculation Research and development expense / revenue. Period ending 2025-03-31..
  • Stock-based compensation / revenue · 12 months: Value 25.07%; Formula and calculation Share-based compensation / revenue. Period ending 2025-03-31..
  • Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..

Spending and interest coverage

Overview →

Financial period ending 2025-03-31; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
R&D / revenue · 12 months16.92%Research and development expense / revenue. Period ending 2025-03-31.

$3.69M ÷ $21.79M × 100 ≈ 16.92%

Stock-based compensation / revenue · 12 months25.07%Share-based compensation / revenue. Period ending 2025-03-31.

$5.46M ÷ $21.79M × 100 ≈ 25.07%

Interest coverage · 12 months(m)Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Research and development spending3.69M USDResearch and Development Expense
Revenue21.79M USD
Stock-based compensation5.46M USDShare-based Payment Arrangement, Noncash Expense
Operating income-30.32M USDOperating Income (Loss)
Interest expense · reported / estimated(m)Interest Expense · Estimated expense assumptions

Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingResearch and development spending (USD)Revenue (USD)Stock-based compensation (USD)Operating income (USD)Interest expense · reported / estimated (USD)R&D / revenueSBC / revenueInterest coverageInterest expense basis
2025-03-31$3.69M$21.79M$5.46M$-30.32M(m)16.92%25.07%(m)(m)
2024-12-31$3.37M$19.70M$5.25M$-24.13M(m)17.09%26.65%(m)(m)
2024-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2024-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2024-03-31(m)(m)(m)(m)$8.26M(m)(m)(m)Reported
2023-12-31(m)(m)(m)(m)$9.42M(m)(m)(m)Reported
2023-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-03-31$3.55M(m)$2.49M$-14.67M$2.02M(m)(m)-7.26×Reported
2022-12-31$4.11M(m)$2.40M$-15.11M$7.00K(m)(m)-2158.29×Reported
2022-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-03-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-12-31(m)(m)$11.92M(m)(m)(m)(m)(m)(m)
2021-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-03-31$3.54M(m)$14.13M$-19.35M$3.20M(m)(m)-6.06×Reported
2021-01-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-12-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-09-30$2.55M(m)$10.94M$-14.98M$2.90M(m)(m)-5.16×Reported
2020-06-30$2.88M(m)$11.74M$-15.30M$2.21M(m)(m)-6.93×Reported
2020-03-31$1.83M$100.00K$4.50M$-7.84M$1.50M1826.14%4496.17%-5.23×Reported
2019-12-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-03-31$712.12K$504.79K$1.01M$-2.61M$1.12M141.07%201.01%-2.33×Reported
2018-12-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2018-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.